Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Ligand Pharmaceuticals Incorporated (LGND)


Recently stock market analysts have updated their consensus ratings on shares of Ligand Pharmaceuticals Incorporated (LGND).

Most recent broker ratings

10/05/2016 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 160 price target on the stock.

09/27/2016 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 150 price target on the stock.

09/07/2016 – Ligand Pharmaceuticals Incorporated was upgraded to “hold” by analysts at Deutsche Bank. They now have a USD 105 price target on the stock.

04/13/2016 – Stephens began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “overweight” rating. They now have a USD 150 price target on the stock.

03/11/2016 – Sidoti began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “buy” rating. They now have a USD 140 price target on the stock.

06/19/2015 – Ligand Pharmaceuticals Incorporated had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 93 price target on the stock.

05/20/2015 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Craig-Hallum. They now have a USD 105 price target on the stock.

05/05/2015 – Ligand Pharmaceuticals Incorporated was downgraded to “sell” by analysts at Zacks.

03/03/2015 – Ligand Pharmaceuticals Incorporated was upgraded to “buy” by analysts at CRT Capital. They now have a USD 102 price target on the stock.

07/22/2014 – Empire Asset Management began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “sell” rating. They now have a USD 16 price target on the stock.

04/28/2014 – Ligand Pharmaceuticals Incorporated was upgraded to “neutral” by analysts at Ned Davis Research.

03/24/2014 – Brinson Patrick began new coverage on Ligand Pharmaceuticals Incorporated giving the company a “outperform” rating.

02/24/2014 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at Summer Street. They now have a USD 91 price target on the stock.

02/13/2014 – Ligand Pharmaceuticals Incorporated was upgraded to “buy” by analysts at TheStreet.

02/13/2014 – Ligand Pharmaceuticals Incorporated had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 96 price target on the stock.

Ligand Pharmaceuticals Incorporated has a 50 day moving average of 106.05 and a 200 day moving average of 116.56. The stock’s market capitalization is 1.97B, it has a 52-week low of 82.06 and a 52-week high of 139.79.

The share price of the company (LGND) was up +1.21% during the last trading session, with a high of 95.94 and the volume of Ligand Pharmaceuticals Incorporated shares traded was 211529.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.